{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:49:25Z","timestamp":1789674565617,"version":"4.0.1"},"reference-count":41,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Early diagnosis of natalizumab-related progressive multifocal leucoencephalopathy (NTZ-PML) in multiple sclerosis has been deemed a major priority by the regulatory agencies but has yet to become a reality. The current paper aims to: (1) investigate whether patients with NTZ-PML pass through a prolonged presymptomatic phase with MRI abnormalities, (2) estimate the longitudinal PML lesion volume increase during the presymptomatic phase and (3) estimate the presymptomatic phase length and its impact on therapy duration as a risk stratification parameter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All Italian patients who developed NTZ-PML between 2009 and 2018 were included. The data of patients with available prediagnostic MRI were analysed (n=41). Detailed clinical and neuroradiological information was available for each participant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>(1) PML lesions were detectable in the presymptomatic phase in 32\/41 (78%) patients; (ii) the lesion volume increased by 62.8 % for each month spent in the prediagnostic phase; (3) the prediagnostic phase length was 150.8\u00b174.9 days; (4) PML MRI features were detectable before the 24th month of therapy in 31.7 % of patients in our cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Considering the latency of PML clinical manifestation, the presymptomatic phase length supports the usefulness of MRI surveillance every 3\u20134 \u2009months. Early diagnosis could prompt a better outcome for patients due to the relationship between lesion volume and JC virus infection. The insight from this study might also have an impact on risk stratification algorithms, as therapy duration as a parameter of stratification appears to need reassessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2018-319208","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T12:17:34Z","timestamp":1541161054000},"page":"261-267","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution"],"prefix":"10.1136","volume":"90","author":[{"given":"Cristina","family":"Scarpazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Signori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Prosperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Cosottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero","family":"Capra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Gerevini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"key":"2023072002302528000_90.3.261.1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","article-title":"Classifying PML risk with disease modifying therapies","volume":"12","author":"Berger","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"2023072002302528000_90.3.261.2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000541"},{"key":"2023072002302528000_90.3.261.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044396"},{"key":"2023072002302528000_90.3.261.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.21"},{"key":"2023072002302528000_90.3.261.5","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"key":"2023072002302528000_90.3.261.6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-311100"},{"key":"2023072002302528000_90.3.261.7","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrneurol.2017.161","article-title":"Multiple sclerosis: progressive multifocal leukoencephalopathy risk stratification","volume":"13","author":"Pitarokoili","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"2023072002302528000_90.3.261.8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","article-title":"Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification","volume":"88","author":"Schwab","year":"2017","journal-title":"Neurology"},{"key":"2023072002302528000_90.3.261.9","doi-asserted-by":"crossref","unstructured":"Major EO , Nath A . A link between long-term natalizumab dosing in MS and PML: putting the puzzle together. Neurol Neuroimmunol Neuroinflamm 2016;3:e235.doi:10.1212\/NXI.0000000000000235","DOI":"10.1212\/NXI.0000000000000235"},{"key":"2023072002302528000_90.3.261.10","doi-asserted-by":"crossref","unstructured":"Kr\u00e4mer J , Tenberge JG , Kleiter I , et al . Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? PLoS One 2017;12:e0174858.doi:10.1371\/journal.pone.0174858","DOI":"10.1371\/journal.pone.0174858"},{"key":"2023072002302528000_90.3.261.11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(18)30122-4","article-title":"Understanding risk of PML through multiple sclerosis","volume":"17","author":"Martin","year":"2018","journal-title":"Lancet Neurol"},{"key":"2023072002302528000_90.3.261.12","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1212\/WNL.0000000000004485","article-title":"Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients","volume":"89","author":"Plavina","year":"2017","journal-title":"Neurology"},{"key":"2023072002302528000_90.3.261.13","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515570768"},{"key":"2023072002302528000_90.3.261.14","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.604"},{"key":"2023072002302528000_90.3.261.15","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.4"},{"key":"2023072002302528000_90.3.261.16","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-015-0316-4"},{"key":"2023072002302528000_90.3.261.17","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.114"},{"key":"2023072002302528000_90.3.261.18","doi-asserted-by":"crossref","unstructured":"Prosperini L , de Rossi N , Scarpazza C , et al . Natalizumab-Related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an italian independent registry. PLoS One 2016;11:e0168376.doi:10.1371\/journal.pone.0168376","DOI":"10.1371\/journal.pone.0168376"},{"key":"2023072002302528000_90.3.261.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30040-1"},{"key":"2023072002302528000_90.3.261.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6426-5"},{"key":"2023072002302528000_90.3.261.21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31826846b4"},{"key":"2023072002302528000_90.3.261.22","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ana.25070","article-title":"To do or not to do? Plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy","volume":"82","author":"Scarpazza","year":"2017","journal-title":"Ann Neurol"},{"key":"2023072002302528000_90.3.261.23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40893-016-0018-7","article-title":"The still under-investigated role of cognitive deficits in PML diagnosis","volume":"2","author":"Scarpazza","year":"2017","journal-title":"Mult Scler Demyelinating Disord"},{"key":"2023072002302528000_90.3.261.24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828c2fa1"},{"key":"2023072002302528000_90.3.261.25","doi-asserted-by":"crossref","unstructured":"Wijburg MT , Warnke C , Barkhof F , et al . Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. J Neurol Neurosurg Psychiatry 2018:jnnp-2018-318261.doi:10.1136\/jnnp-2018-318261","DOI":"10.1136\/jnnp-2018-318261"},{"key":"2023072002302528000_90.3.261.26","doi-asserted-by":"crossref","unstructured":"Wijburg MT , Kleerekooper I , Lissenberg-Witte BI , et al . Association of progressive multifocal leukoencephalopathy lesion volume with JC virus polymerase chain reaction results in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. JAMA Neurol 2018;75:827.doi:10.1001\/jamaneurol.2018.0094","DOI":"10.1001\/jamaneurol.2018.0094"},{"key":"2023072002302528000_90.3.261.27","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-313772"},{"key":"2023072002302528000_90.3.261.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2013.02.002"},{"key":"2023072002302528000_90.3.261.29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"2023072002302528000_90.3.261.30","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23676"},{"key":"2023072002302528000_90.3.261.31","doi-asserted-by":"publisher","DOI":"10.1155\/2000\/421719"},{"key":"2023072002302528000_90.3.261.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2008.09.031"},{"key":"2023072002302528000_90.3.261.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"2023072002302528000_90.3.261.34","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-315298"},{"key":"2023072002302528000_90.3.261.35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult Scler"},{"key":"2023072002302528000_90.3.261.36","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.157"},{"key":"2023072002302528000_90.3.261.37","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/1352458516681505","article-title":"High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO","volume":"23","author":"Enzinger","year":"2017","journal-title":"Mult Scler"},{"key":"2023072002302528000_90.3.261.38","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2018.0004","article-title":"Progressive multifocal leukoencephalopathy lesions and JC virus: the limits and value of imaging","volume":"75","author":"Major","year":"2018","journal-title":"JAMA Neurol"},{"key":"2023072002302528000_90.3.261.39","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000200"},{"key":"2023072002302528000_90.3.261.40","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/WNL.0000000000003740","article-title":"No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML","volume":"88","author":"Landi","year":"2017","journal-title":"Neurology"},{"key":"2023072002302528000_90.3.261.41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jns.2017.05.018","article-title":"Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?","volume":"378","author":"Scarpazza","year":"2017","journal-title":"J Neurol Sci"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2018-319208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T05:40:48Z","timestamp":1689831648000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2018-319208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2,14]]},"published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1136\/jnnp-2018-319208"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2018-319208","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]}}}